These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24877866)

  • 1. Averting hepatocellular carcinoma in chronic hepatitis B with antiviral therapy: tipping the balance or not yet?
    Janssen HL; Arif A
    Gastroenterology; 2014 Jul; 147(1):24-6. PubMed ID: 24877866
    [No Abstract]   [Full Text] [Related]  

  • 2. The 5-year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    Wang S; Fang S; Liu Y
    J Viral Hepat; 2021 Sep; 28(9):1333-1334. PubMed ID: 34051028
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
    Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
    Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent hepatocellular carcinoma: it's the virus!
    Kim WR; Gores GJ
    J Clin Oncol; 2013 Oct; 31(29):3621-2. PubMed ID: 24002518
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatocellular carcinoma associated with continuous and discontinuous application of nucleoside analogues in the treatment of chronic hepatitis B].
    Duan S; Bao Z; Yuan X; Liu M; Wang L; Xiao M
    Zhonghua Gan Zang Bing Za Zhi; 2014 Jun; 22(6):462-4. PubMed ID: 25282732
    [No Abstract]   [Full Text] [Related]  

  • 6. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
    Hiramatsu N; Yamada R; Takehara T
    J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.
    Yin J; Li N; Han Y; Xue J; Deng Y; Shi J; Guo W; Zhang H; Wang H; Cheng S; Cao G
    J Clin Oncol; 2013 Oct; 31(29):3647-55. PubMed ID: 24002499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
    J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
    Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
    J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
    Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
    Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatocellular carcinoma resulting from hepatitis B: are we there yet?
    Di Bisceglie AM
    Clin Gastroenterol Hepatol; 2014 May; 12(5):894-6. PubMed ID: 24316105
    [No Abstract]   [Full Text] [Related]  

  • 13. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
    Wei L; Kao JH
    Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Seroclearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in hepatitis B virus patients during nucleoside/nucleotide analog therapy].
    Watanabe H; Ueno Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():459-65. PubMed ID: 26845978
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: safe and effective cessation of long-term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2015 Jan; 41(2):236-7. PubMed ID: 25511775
    [No Abstract]   [Full Text] [Related]  

  • 16. Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation.
    Lee WC; Chou HS; Lee CS; Wu TH; Wang YC; Cheng CH; Lee CF; Wu TJ; Chan KM
    J Viral Hepat; 2018 Jul; 25(7):874-877. PubMed ID: 29431877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacologic therapies in chronic hepatitis B.
    Hongthanakorn C; Lok AS
    Gastroenterol Clin North Am; 2010 Sep; 39(3):659-80. PubMed ID: 20951923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs.
    Janssen HL; Lau GK
    Hepatology; 2005 Dec; 42(6):1459; author reply 1459-60. PubMed ID: 16317685
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.